Contributor Page
Ropes & Gray LLP
Email  |  Website  |  Articles
Contact Details
Tel: +1 212 5969000
Fax: +1 212 5969090
1211 Avenue of the Americas
New York
New York
NY 10036-8704
United States
By Marc Rubenstein, Melissa Rones
The panelists provide lessons learned and perspectives of different stakeholders in the due diligence process.
By Ropes & Gray LLP's FDA Regulatory Practice, Ropes & Gray LLP's Health Care Practice
The United States Food & Drug Administration (FDA) has issued a guidance document announcing its intention not to object to an IRB's waiving or altering the informed consent requirements for an FDA-regulated clinical investigation that presents no more than minimal risk and involves adequate human subjects protections.
By Zachary Brez, Marcus Thompson, Michael S. Casey, Brendan Hanifin, Emerson Siegle
On July 20, 2017, the U.S. Treasury Department's Office of Foreign Assets Control ("OFAC") penalized ExxonMobil Corp. and two of its U.S. subsidiaries (collectively, "ExxonMobil") $2 million for violations of the Ukraine-Related Sanctions Regulations.
By David Seymour
Real estate is an operational asset by its very nature and it has many touchpoints with the various parties involved in its lifecycle.
By Ropes & Gray LLP's Private Equity Practice
With the year half over, it's still too early to say whether it's going to be a good one or a difficult one for the private equity market.
By David Seymour
David Seymour, Ropes & Gray real estate partner, analyses the new register of overseas beneficial owners of UK real estate.
By Ropes & Gray LLP's Securities & Public Companies Practice
After more than six years of outreach and public comment, on June 1, 2017, the PCAOB adopted a new auditor reporting standard that, if approved by the SEC, would significantly expand the existing auditor's report.
By Philip Sanderson
Businesses in the UK are invariably bought and sold using an auction process, and so I am going to talk about the evolution in the auction process in the UK and draw out certain themes...
By Andrew Howard
The UK's new corporate offence of failure to prevent facilitation of tax evasion is quite a mouthful, but the title does do a pretty accurate job of describing the offence.
By Michael B. Lampert
Much has been made about how the fraud and abuse laws, which were designed in order to prevent abusive arrangements that exploited the historic reimbursement models, can or should be applied...
By Deborah Monson, Jeremy A. Liabo
The new notice filing requirement for continued reliance on certain exemptions from aggregation under the CFTC's position limit rules becomes effective on August 14, 2017.
By Brien O'Connor, Andrew O’Connor, Emily Honig
This week, the U.S. Department of Justice and Drug Enforcement Administration announced a $35 million settlement with a major pharmaceutical manufacturer to resolve alleged failures to monitor and report...
By Ropes & Gray LLP
Beginning in 2018, most public companies will be required to include CEO pay ratio disclosure in their proxy statements.
By Michael B. Lampert
When I think about developing a value-based program for pharmaceuticals it's necessary first, I think, to look at what they need practically to do to make that work.
By Ruchit Patel
Ruchit Patel, Ropes & Gray antitrust partner, examines excessive pricing laws in the EU and the increase of cases involving generic pharmaceuticals.
Contributor's Topics